Abstract. Patients with glutaric aciduria (GA) have greatly increased urinary excretion ofglutarate. Their leukocyte and fibroblast sonicates have deficient ability to produce 'CO2 from [l,5-14C]glutaryl-CoA, an enzymatic process with two sequential reaction steps, dehydrogenation and decarboxylation. In normal individuals, it is not known whether these two reaction steps require one or two enzymes, and currently it is assumed that a single enzyme, glutaryl-CoA dehydrogenase (GDH), carries out these two reactions. Since GA patients also excrete increased amounts of 3-hydroxylglutarate and glutaconate in urine, it was throught that glutaryl-CoA in these patients may be dehydrogenated but not decarboxylated. We developed a new assay specific for glutaryl-CoA dehydrogenation which measures enzyme-catalyzed tritium release from [2,3,4_3H]glutaryl-CoA, and we studied the glutarylCoA dehydrogenating activity in cultured normal human fibroblasts and those from patients with GA. The Michaelis constant (K.) of normal human fibroblast GDH for [2,3,4-3H]glutaryl-CoA was 5.9 pM, and activity was severely inhibited by (methylenecyclopropyl)acetyl-CoA at low concentrations. Sonicates from all five GA fibroblast lines examined showed 2-9% of control glutarylCoA dehydrogenating activity, corresponding to the deficient '4C02 releasing activity. These results indicate either that the conversion ofglutaryl-CoA to crotonyl-CoA is accomplished by two enzymes, and patients with GA are deficient in the activity of the first component, or alternatively, that this process is carried out by a single
Introduction
The inherited metabolic disorder, glutaric aciduria (GA),' was first identified by Goodman et al. (1) in two siblings with intermittent metabolic acidosis who had accumulation in blood and excessive urinary excretion of glutaric acid. These children, as well as others subsequently described (2-4), developed progressive dystonia and dyskinesia within the first few months of life. In these patients, the accumulation of glutarate is due to a deficient oxidizing activity for glutaryl-CoA, an intermediate in the metabolism of lysine, hydroxylysine, and tryptophan ( Fig.   1 ) (5, 6) . Further metabolism ofglutaryl-CoA occurs via glutarylCoA dehydrogenase (GDH), a flavine adenine dinucleotide (FAD)-containing mitochondrial enzyme found mainly in the liver and kidney. It is believed that this enzyme catalyzes the conversion of glutaryl-CoA to crotonyl-CoA by two successive reactions, namely dehydrogenation of glutaryl-CoA to glutaconyl-CoA, and decarboxylation of the glutaconyl-CoA. It is not known at present whether these two reactions are catalyzed by a single enzyme or by two enzymes. Thus far, these two activities of the partially purified bovine and rat enzymes have been inseparable (7, 8) .
In studying the nature of the enzyme in patients with GA, a problem arises in measuring the dehydrogenating activity. Pure and partially purified acyl-CoA dehydrogenases are usually assayed spectrophotometrically, measuring reduction of an electron-accepting dye, such as dichloroindophenol. By using crude cell homogenates as an enzyme source, nonspecific dye reduction occurs, and this makes accurate measurement of dehydrogenation impossible. Thus, previous assays ofhuman GDH measure 14CO2 release from [1 ,5- <10% of control, and in four of the lines, the activity was <5% of control, with activities ranging from 0.26±0.17 to 1.31±0.38 pmol 3H20/min per mg protein. By using the '4C02-release assay, the GA cell lines had residual activity ranging from 0 to 5% of control. Very low levels of activity in GA fibroblasts were difficult to measure using the tritium-release assay because the background radioactivity became large relative to the radioactive product formation. Thus, kinetic studies on the mutant enzyme using the tritium-release method could not be performed.
IVDH activity was assayed in the cell lines by a tritiumrelease assay under the same conditions used in the GDH assay. As expected, <5% of control activity (Table II) 
Discussion
Increased urinary excretion of glutaric acid occurs in at least two inherited metabolic diseases, GA and glutaric aciduria type II (GA II). For this study, we used cell lines from patients with GA. In these patients, the urinary organic acid pattern shows an elevation mainly of glutaric acid and its metabolites, 3-hydroxylglutaric and glutaconic acids, and this disease takes a distinctive neurodegenerative course. The urinary glutaric acid is presumably derived from glutaryl-CoA by enzymatic hydrolysis of its coenzyme A ester. Glutaryl-CoA, a common intermediate in the degradative pathways of lysine, hydroxylysine, and tryptophan, is normally converted to crotonyl-CoA by a mitochondrial enzyme or enzymes capable of dehydrogenation and decarboxylation. The precise mechanism of this reaction 
Values are expressed as mean±SD. The numbers in parenthesis indicate the numbers of experiments performed. Abbreviations are as follows:
GA, glutaric aciduria fibroblasts; IVA, isovaleric acidemia fibroblasts; ND, not determined.
or reactions is currently unknown. GA may provide a useful experimental model for studying this aspect oflysine degradation, since cell homogenates and liver mitochondria from patients with GA lack the ability to convert glutaryl-CoA to crotonylCoA (1, 5, 6, 9). However, it could not be determined from these studies which step, dehydrogenation or decarboxylation, was defective.
In contrast, patients with GA II, first described by Przyrembel et al. ( 16), have increased urinary excretion of numerous organic acids in addition to glutaric acid. This seems to be caused by a defect in the degradation of fatty acids and of several amino acids at the level of acyl-CoA dehydrogenation (16). Unlike in GA, oxidation of [1 ,5-'4C]glutaryl-CoA to crotonyl-CoA is normal in cell homogenates from GA type II patients (17). Rather, the dysfunction of the several acyl-CoA dehydrogenases has been suggested to be due to defective electron-transfer flavoprotein (17), a cofactor required for these dehydrogenases, or electron-transfer flavoprotein dehydrogenase (18) .
The tritium-release assay that we developed directly measures glutaryl-CoA dehydrogenating activity of crude cell homogenates. In contrast, measuring the "'CO2 release from [1,5-"'C]glutaryl-CoA estimates the dehydrogenase activity indirectly. The "'C02-release assay, exclusively, had been used in human studies ofGDH, since crude homogenates of liver and fibroblasts cannot be assayed directly for dehydrogenation by a dye-reduction assay. Conventional dye-reduction assays show nonspecific dye reduction when used to assay crude cell homogenates, due mainly to free CoA-SH generated from acyl-CoA esters by the action of thioesterases. The tritium-release assay, which is adaptable to several acyl-CoA dehydrogenases, eliminates this problem and can quantitate activity in disrupted fibroblasts. However, the original procedure of Rhead and Tanaka (14) and Rhead et al. (15) required isolating fibroblast mitochondria, and the separation of sufficient mitochondria from fibroblasts required a large amount ofcells. In the present study, we used parallel reactions in which acyl-CoA dehydrogenation is inhibited by MCPA-CoA to adjust for the increase in background radioactivity which occurred with increased protein concentration in the reaction mixture. With the subtraction of this background value, reliable activity measurements can be made on crude cell homogenates, and activity measurements could be determined on cells from a single tissue culture flask.
Our data demonstrate that in five GA cell lines from three unrelated pedigrees, there is defective dehydrogenation as well as decarboxylation of glutaryl-CoA. IVDH activity was maintained at normal levels in these cell lines, confirming the specificity of the metabolic derangement in GA. Since the enzymes involved in the conversion of glutaryl-CoA to crotonyl-CoA have not been fully characterized or purified, the exact nature of this deficiency is not known. At present, there are two possible interpretations of this data: one is that dehydrogenation of glutaryl-CoA and subsequent decarboxylation of glutaconyl-CoA are catalyzed by two separate enzymes and GA patients are deficient in the former activity. The second possibility is that these two reactions are carried out by a single enzyme which is deficient in patients with GA. Gomes et al. (19) have suggested a coordinated reaction mechanism for the bacterial enzyme, which apparently is a single protein. No similar mechanistic studies have been accomplished by using a mammalian enzyme source, but evidence strongly supporting a single enzyme hypothesis has been obtained from studies on bovine (7) and rat (8) liver mitochondria: dehydrogenase and decarboxylase activities copurify with each of several successive purification steps. In humans, the apparent Kim as measured by the tritium-release assay, for glutaryl-CoA dehydrogenation is 5.9 MM, and a Km of 15.7 1AM has been reported by Christensen and Brandt (6) for the dehydrogenation/decarboxylation reaction. Since two sequential reactions are involved in the latter determination and since the Km for the decarboxylation reaction alone has not been determined, no further conclusions about the enzyme mechanism are possible from the Km data.
Even with relatively low specific activity sources for GDH and IVDH, such as fibroblasts, we were able to show clear differences in enzyme activities between mutant and normal cells using the tritium-release assay. Unfortunately, fibroblasts from obligate heterozygotes were not available for testing. Additionally, the sensitivity of the assay was insufficient to allow performing kinetic analysis on the residual activity of the mutant enzymes obtained from cultured fibroblasts. To do that, liver mitochondrial sonicates, which have roughly 20-fold higher specific activity for GDH than crude fibroblast sonicates, would be the better enzyme source.
Because the neurodegenerative picture in GA may be related to the toxicity ofglutarate metabolites, understanding the mechanism of formation ofthese metabolites may be important. (1 1,  12 ). Several other acyl-CoA dehydrogenases in addition to GDH are severely inhibited in hypoglycin poisoning, and the urinary metabolic pattern in hypoglycin poisoning is virtually identical to that of GA II. It is interesting that glutaconate and 3-hydroxylglutarate do not appear in urine of patients with either GA II or in urine of hypoglycin-treated rats (D. Hine and K. Tanaka, unpublished observation). In this report, we demonstrated strong inhibition ofGDH by micromolar concentrations of MCPA-CoA. MCPA-CoA has previously been shown to be a "suicide" inhibitor of purified general acyl-CoA dehydrogenase (20). In our assay system in which glutaryl-CoA and MCPACoA were simultaneously added to cell homogenates, the inhibition appeared competitive, with an apparent Ki of I pM. This is probably due to the MCPA-CoA competing with the substrate for the initial binding to GDH, which is necessary before inactivation of the enzyme occurs.
